Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) (NCT03821376) | Clinical Trial Compass
TerminatedPhase 4
Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)
Stopped: Study stopped due to staffing issues that impacted ability to recruit.
United States12 participantsStarted 2019-07-16
Plain-language summary
Patients with renal lesions suspicious for renal cell carcinoma (RCC) have a variety of different treatment pathways available to them. Imaging surveillance is being used frequently on smaller renal masses, and radiologists are being asked to biopsy more renal lesions to better guide decision making by urology. This is in large part due to the pathologic grade of renal masses having been shown to correlate with patient outcomes. The World Health Organization (WHO) or Fuhrman grade is the standard grading scale used by pathologists for RCC. The goal of this study will be to correlate contrast enhanced ultrasound findings with the pathologic grade of RCC. Specifically, the investigators hypothesize that tumors with different pathologic grades will show different patterns of qualitative enhancement, as well as different perfusion kinetics.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Greater than or equal to 18 years of age
* Previously identified renal mass with radiology and clinical features consistent with RCC
* Clinical care plan includes partial or total nephrectomy
Exclusion Criteria:
* Less than 18 years of age
* Currently pregnant
* Renal mass with clinical care plan that does not include nephrectomy
* Renal mass suspected to be non RCC neoplasm by imaging and clinical data
* Renal mass unable to be visualized by grayscale ultrasound
* Known renal vein thrombosis
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Contrast Enhanced Ultrasound Features of Renal Masses (Time to Peak, Mean Transit Time)
Timeframe: 6 months
2
Contrast Enhanced Ultrasound Features of Renal Masses (Peak Intensity)